News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|December 23, 2024

Overview of PPD and Current Management Practices

Author(s)Carmen Kosicek, MSN, PMHNP-BC, Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss how postpartum depression (PPD) is recognized and managed, highlighting current diagnostic practices, treatment options, and the role of emerging therapies in improving outcomes for affected individuals.

Episodes in this series

EP. 1 Overview of PPD and Current Management Practices

EP. 1 Overview of PPD and Current Management Practices

EP. 2 New FDA-Approved Treatments for PPD

EP. 2 New FDA-Approved Treatments for PPD

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 4 Diagnostic Tools for PPD

EP. 4 Diagnostic Tools for PPD

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

postpartum depression

EP. 10 Experts Share Top 7 Recommendations for Treating Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Experts featured in this series.

Multidisciplinary Approaches to Long-Term Narcolepsy Care

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 22nd 2026

Experts featured in this series.

Optimizing Narcolepsy Treatment Through Polypharmacy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Assessing DEA Scheduling and Emerging Therapies in Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Evaluating Pitolisant and Other Pharmacologic Treatment Options for Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 8th 2026

Experts featured in this series.

Narcolepsy Treatment Considerations in Pediatric Patients

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 8th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?